"label","description","instanceType","id","name","text","uuid:ID"
"","Main objective","Objective","Objective_1","OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","5a493e22-5e06-4d24-b103-b15bceb1d8c2"
"","Safety","Objective","Objective_2","OBJ2","To document the safety profile of the xanomeline TTS.","a8f81034-34ae-4eb7-b0f2-7dd6688eca4a"
"","Behaviour","Objective","Objective_3","OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","cbeb623f-f665-4c30-862e-b2601814b49c"
"","","Objective","Objective_4","OBJ4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","fbd8db53-a25a-4b5e-800e-f2acccdbc412"
"","","Objective","Objective_5","OBJ5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","cd813a79-bc6e-49dc-b7b8-58712633d7cd"
"","","Objective","Objective_6","OBJ6","To assess the treatment response as a function of Apo E genotype.","04662925-54d9-4914-b17b-2cf9b1fac771"
